Glaxo-Smith-Kline, the makers of Alli, reported 4 million people have purchased the former prescription-only weight loss drug in the past year.  It’s not bad, but compared to what analysts expected, it’s “underwhelming.”

Can’t say I’m particularly surprised though, in view of the documented side effects.  No wonder GSK is looking to regulate the competition out of existence.

Share